Search | Page 33 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. What are the treatments for PNH?

    ... , the destruction of red blood cells. Bone marrow/stem cell transplantation (BMT/SCT):  A procedure that replace your unhealthy ...

    FAQ last updated 03/15/2016 - 11:32pm.

  2. Recurrent and Secondary MDS

    ... after medical treatments, and even after an allogeneic stem cell transplant . So, I think of recurrent MDS to mean progression or ...

    Interview last updated 10/24/2012 - 1:12pm.

  3. Extended Dosing With Eltrombopag for Severe Aplastic Anemia

    ... treated with immunosuppressive drug regimens or allogeneic stem cell transplantation. However, 20-40% of patients are ineligible for transplant ...

    Clinical Trial last updated 04/26/2016 - 9:36am.

  4. Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (DFCI 10-106)

    ... and cyclophosphamide , the drugs used during stem cell collection and transplant, are also approved by the FDA. Melphalan is an ...

    Clinical Trial last updated 05/23/2016 - 3:45pm.

  5. An Open-label Study of Lirilumab (BMS-986015) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia

    ... renal transplant) are excluded Patients with allogeneic stem cell transplantation within the last 6 months and patients with active GVHD ...

    Clinical Trial last updated 06/06/2016 - 1:26pm.

  6. Transplantation Update

    ... toxicity from the regimens used to prepare patients for stem cell transplants regardless of who the donor is or the source of stem cells ...

    Interview last updated 05/14/2015 - 2:42pm.

  7. Allo HSCT Using RIC for Hematological Diseases

    ... regimen followed by a related or unrelated donor stem cell infusion. The primary objective is to evaluate rates of acute ...

    Clinical Trial last updated 05/02/2016 - 9:29am.

  8. HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA)

    ... dependence* ANC <1000 x 109/L Hgb <8 gm/dl or red cell transfusion dependence* Myelodysplastic Syndrome (MDS) (based on ... neupogen Biological: Peripheral blood stem cell The source of stem cells for all patients will be peripheral ...

    Clinical Trial last updated 05/09/2016 - 3:19pm.

  9. Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

    ... Malignant conditions for which CD34+ selected, T-cell depleted allogeneic hematopoietic stem cell transplantation is indicated such as: AML in 1st remission - ...

    Clinical Trial last updated 04/29/2016 - 1:59pm.

  10. Treating Higher-Risk Myelodysplastic Syndromes

    ... of MDS subtypes and whether the patient is dependent on red cell transfusions. In the WPSS, a score of three or above is considered ... the eventual goal or desired treatment is an allogeneic stem cell transplant . Depending on patient’s age and the stage or status ...

    Interview last updated 05/18/2012 - 1:55pm.